TLDR Kindly MD (NAKA) postponed its Q3 earnings report filing past the November 14 deadline, citing complicated merger accounting Preliminary figures show a $59 million loss on the Nakamoto Holdings acquisition plus $22 million in unrealized crypto losses The stock fell 10% to $0.55 after the announcement, down 95% over the past six months The [...] The post Kindly MD (NAKA) Stock: Earnings Report Delayed as $59 Million Merger Loss Surfaces appeared first on Blockonomi.TLDR Kindly MD (NAKA) postponed its Q3 earnings report filing past the November 14 deadline, citing complicated merger accounting Preliminary figures show a $59 million loss on the Nakamoto Holdings acquisition plus $22 million in unrealized crypto losses The stock fell 10% to $0.55 after the announcement, down 95% over the past six months The [...] The post Kindly MD (NAKA) Stock: Earnings Report Delayed as $59 Million Merger Loss Surfaces appeared first on Blockonomi.

Kindly MD (NAKA) Stock: Earnings Report Delayed as $59 Million Merger Loss Surfaces

2025/11/18 20:11
3 min read

TLDR

  • Kindly MD (NAKA) postponed its Q3 earnings report filing past the November 14 deadline, citing complicated merger accounting
  • Preliminary figures show a $59 million loss on the Nakamoto Holdings acquisition plus $22 million in unrealized crypto losses
  • The stock fell 10% to $0.55 after the announcement, down 95% over the past six months
  • The company holds 5,765 BTC and became a bitcoin treasury vehicle after merging with Nakamoto Holdings in August
  • A $21.85 million gain from reduced contingent liabilities provides some offset to the substantial losses

Kindly MD notified regulators Friday it would miss the deadline for filing its third quarter financial results. The company needs extra time to finalize accounting related to its Nakamoto Holdings merger.


NAKA Stock Card
Kindly MD, Inc., NAKA

The SEC filing revealed preliminary loss figures that spooked investors. Shares dropped 10% to $0.55 on Monday following the announcement.

The healthcare company turned bitcoin treasury vehicle plans to submit its Form 10-Q within the five-day extension window. SEC rules allow this grace period for companies facing filing difficulties.

Merger Accounting Creates $59 Million Write-Down

The Nakamoto acquisition generated a $59 million loss for Kindly MD. This write-down means the company paid $59 million more than the acquired assets were worth.

David Bailey’s Nakamoto Holdings merged with Kindly MD in August 2025. Bailey became CEO of the combined entity, which now focuses on bitcoin treasury operations.

The company’s bitcoin holdings stand at 5,765 BTC. This makes Kindly MD the 19th largest bitcoin treasury company by holdings.

Crypto-related losses extend beyond the acquisition write-down. Unrealized losses on digital assets total $22.07 million for the quarter.

Kindly MD also recorded a $1.41 million realized loss from selling crypto assets. These transactions locked in actual losses during the three-month period.

Debt and Liability Changes Add to Financial Picture

The company expects to report a $14.45 million loss on debt extinguishment. This hit comes from restructuring obligations tied to the merger.

One positive item appears in the preliminary results. Kindly MD anticipates a $21.85 million gain from changes in contingent liability fair value.

This gain represents a reduction in what the company owes. The liability decreased in value during the quarter, creating an accounting benefit.

The stock has collapsed since the merger closed. Shares traded 95% below their price from six months ago.

Weekly performance showed a 25% decline leading up to Monday’s drop. Investors reacted negatively to both the filing delay and preliminary loss disclosure.

Kindly MD originally operated as an integrated healthcare services provider. The Nakamoto merger completely changed the company’s business model and strategic direction.

The accounting complexity stems from applying US GAAP standards to digital asset holdings. Bitcoin requires mark-to-market treatment that creates volatility in financial statements.

PCAOB review requirements add another layer of complexity. Public company audits must meet specific standards that take time to complete properly.

Bailey has stayed quiet about the stock decline and earnings delay. His recent public comments focused on other business ventures outside Kindly MD.

The company had 45 days to file its quarterly report under standard SEC timelines. Missing this deadline triggers additional regulatory scrutiny and compliance requirements.

The post Kindly MD (NAKA) Stock: Earnings Report Delayed as $59 Million Merger Loss Surfaces appeared first on Blockonomi.

Market Opportunity
Nakamoto Games Logo
Nakamoto Games Price(NAKA)
$0.07831
$0.07831$0.07831
-0.10%
USD
Nakamoto Games (NAKA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03